CARE1 Pragmatic Clinical Trial
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Principal Investigator
- Laurence ALBIGES, MD, PhDGustave Roussy, Cancer Campus, Grand Paris
- Intervention
- Nivolumab(drug)
- Enrollment
- 1250 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (30)
- Medical University of Vienna, Vienna, Austria
- Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU), Brno, Czechia
- Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK), Hradec Králové, Czechia
- Fakultní nemocnice Olomouc, University Hospital Olomouc (FNOL), Olomouc, Czechia
- Fakultní nemocnice v Motole, University Hospital Motol (MOTOL), Prague, Czechia
- Institut de Cancérologie de l'Ouest - Angers, Angers, France
- CHU Angers, Angers, France
- Institut Sainte Catherine, Avignon, France
- CH de la Côte Basque, Bayonne, France
- Hôpital Jean Minjoz, Besançon, France
- CHU de Bordeaux Hôpital Saint-André, Bordeaux, France
- Centre François Baclesse, Caen, France
- CH Châlon Sur Saône, Chalon-sur-Saône, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Hôpital Henri Mondor, Créteil, France
- +15 more locations on ClinicalTrials.gov
Collaborators
European Commission · CRIS Cancer Foundation · National Cancer Institute, France · Rennes University Hospital · University Hospital, Essen · Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron · The Netherlands Cancer Institute · Servicio Madrileño de Salud, Madrid, Spain · Hospital Universitario 12 de Octubre · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Medical University of Vienna · FAKULTNI NEMOCNICE OLOMOUC · International Kidney Cancer Coalition · Association pour la Recherche sur les Tumeurs du Rein · Resilience · PRIMAA · Queen Mary University of London
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06364631 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
- RECRUITINGPHASE1, PHASE2NCT07239596Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell CarcinomSuzhou Suncadia Biopharmaceuticals Co., Ltd.
See all trials for Acquired cystic disease-associated renal cell carcinoma →